Results 81 to 90 of about 182,500 (270)
Background Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC).
Andrea Necchi +15 more
doaj +1 more source
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression. [PDF]
ImportanceImmunomodulatory anticancer drugs, such as the anti-programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments.
Lin, Kevin +9 more
core +1 more source
Our study identifies MAGI3 as an intestinal epithelial gatekeeper that restrains inflammation‐associated colorectal tumorigenesis but is itself suppressed under highly inflammatory conditions. MAGI3 deficiency activates the STAT3‐CCL2 signaling, thereby promoting TAM‐mediated immunosuppression and inflammation‐associated colorectal tumor progression ...
Yumeng Yang +12 more
wiley +1 more source
In HCC, ADISSP sustains IKKβ/NF‐κB signaling by inhibiting PPP1CA‐mediated IKKβ dephosphorylation, thereby inducing the expressions of SLC16A3 and CCL20. SLC16A3‐driven lactate remodeling promotes glycolysis, ferroptosis resistance, and M2 macrophage polarization, whereas CCL20 facilitates macrophage recruitment.
Tuan‐Song Zhang +10 more
wiley +1 more source
Pembrolizumab in HER2-Positive Gastric Cancer
Pembrolizumab in HER2-Positive Gastric Cancer The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy ...
Lowery, Maeve +26 more
core +1 more source
18F‐FGln PET/CT imaging serves as a marker of Gln uptake in hepatocellular carcinoma. Tumors with high Gln uptake drive Treg‐mediated immunosuppression and immune evasion during antitumor immunotherapy. Conversely, tumors with low Gln uptake maintain sufficient Gln in the TME, suppressing Tregs and enabling cytotoxic T cells to inhibit tumor growth ...
Yi Liu +8 more
wiley +1 more source
Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events.
Tomoya Harada +10 more
doaj +1 more source
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Pembrolizumab in endometrial cancer: Where we stand now
Recently, immunotherapy has shown promising results in solid tumors. To the best of our knowledge, this is the first systematic review of published literature synthesizing all the available data and evaluating both the efficacy and safety of ...
Georgakopoulou, Vasiliki E. +9 more
core +1 more source

